AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03739021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
Study NCT03337412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire
Study NCT04320537 — intervention group
Intervention type: OTHER
Intervention: abstinence from use of marijuana and other abused drugs
Description: abstinence from use of marijuana use and other abused drugs
Study NCT03138681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is given intravenously twice a day for 14 days
Study NCT03138681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP
Description: ATP (100mg) is given intravenously twice a day for 14 days
Study NCT03951350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program (LMP)
Description: Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~1. Presentation of the project and psychoeducation on depression.~2. Behavior activation.~3. Sleep hygiene habits and careful exposure to sunlight.~4. Physical activity.~5. Adherence to the Mediterranean diet.~6. Summary of previous sessions with practical final suggestions.
Study NCT03951350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)
Description: Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
Study NCT03138681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine
Description: Phosphocreatine (1g) is given intravenously twice a day for 14 days
Study NCT03029390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg
Study NCT00512980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00512980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Study NCT03029390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal).
Study NCT00104234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylgalactosamine 4-sulfatase
Study NCT00104234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo/rhASB
Study NCT00512980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Study NCT00053326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally
Study NCT00053326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study NCT00512980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Study NCT02371941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cromolyn sodium
Description: Oral cromolyn sodium
Study NCT02371941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT03143452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel
Description: 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
Study NCT03143452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine eye drop
Description: 0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
Study NCT00703534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
Study NCT00703534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule. administered as a single dose twice daily for 4 weeks
Study NCT01966718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
Study NCT02865876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated Corneal Cross-linking
Description: All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
Study NCT00703534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelusil®
Description: Chewable tablets taken as needed
Study NCT00703534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gelusil®
Description: Chewable tablets taken as needed
Study NCT01308515 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vanguard Knee System with AS Bearing
Description: FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
Study NCT02865876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Accelerated Corneal Cross-linking
Description: All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
Study NCT01308515 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vanguard Knee System with PS Bearing
Description: FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
Study NCT04092075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF-utilizing powered toothbrush
Description: RF-utilizing Powered toothbrush
Study NCT04092075 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control placebo with no RF
Description: Placebo control, toothbrush with no RF
Study NCT04045002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'MyPinkMom' educational intervention
Description: The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session.
Study NCT00764764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder treatment
Description: shoulder exercise, joint mobilization, home program, posture
Study NCT00764764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder AND cervical treatment
Description: Cervical and shoulder joint mobilization, exercise, posture, and home program
Study NCT00284453 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral blood sampling
Description: blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
Study NCT02194465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally
Study NCT02048319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Description: Pasireotide long acting release, intramuscular injection
Study NCT02048319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration sclerotherapy
Description: Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
Study NCT02048319 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Aspiration sclerotherapy
Description: Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
Study NCT02048319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution, injected as placebo
Study NCT02888938 — intervention group
Intervention type: OTHER
Intervention: pelvic radiography
Study NCT02888938 — intervention group
Intervention type: OTHER
Intervention: pelvic MRI
Study NCT02888938 — intervention group
Intervention type: OTHER
Intervention: pelvic CT-scan
Study NCT04692636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension
Description: BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
Study NCT00097604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Valerian root extract
Description: Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
Study NCT00097604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valerian root extract
Description: Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
Study NCT02194465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally
Study NCT02194465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Administered orally
Study NCT01630538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
Study NCT02618499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timing of administration of post partum Oxytocin
Description: 10 IU of oxytocin given IV at different times after birth
Study NCT02618499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timing of administration of post partum Oxytocin
Description: 10 IU of oxytocin given IV at different times after birth
Study NCT02194465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03647852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
Study NCT03647852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: 1. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
Study NCT03647852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other basic supportive treatment
Description: 1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d
Study NCT03647852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: other basic supportive treatment
Description: 1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d
Study NCT02194465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02451384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine surgery
Description: To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
Study NCT02451384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch surgery
Study NCT03300765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib will be used as induction therapy in experimental arm.
Study NCT03300765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
Study NCT02633774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: AAD(antiarrhythmic drug)
Study NCT02633774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: anti-coagulation
Study NCT00761319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
Study NCT00761319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
Study NCT02451384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study NCT03272776 — intervention group
Intervention type: DEVICE
Intervention: Protector Laryngeal Mask airway
Description: Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
Study NCT02032238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
Study NCT04655170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin (YUPELRI) & Formoterol (Perforomist)
Description: Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
Study NCT02474836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - Atopic subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study NCT02474836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - Non Atopic subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study NCT02474836 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Skin Prick Test - Allergic subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study NCT01373164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study NCT04655170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
Description: Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
Study NCT01373164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study NCT01783691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTT120
Study NCT03043105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, cyclophosphamide and prednisone
Description: * Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year.
Study NCT01373164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01443884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape powder, followed by placebo powder
Description: For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
Study NCT01443884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder followed by grape powder
Description: For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
Study NCT01570764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
Study NCT01570764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
Study NCT04512495 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples will be collected at two times :
Description: * at Baseline,~* after surgery or at the time of post-chemotherapy evaluation.
Study NCT00743106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenoldopam
Description: Fenoldopam (0.1 \~g/kg/min)started during surgery and lasting for a total of 24 hours
Study NCT00743106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
Study NCT03497013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
Study NCT03497013 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, the device was set to turn off after 30 seconds(study model).